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Abstract
Entamoeba histolytica, the parasitic amoeba responsible for amoebiasis, causes approximately 100,000 deaths
every year. There is currently no vaccine against this parasite. We have previously shown that intracecal inoculation
of E. histolytica trophozoites leads to chronic and non-healing cecitis in mice. Entamoeba moshkovskii, a closely
related amoeba, also causes diarrhea and other intestinal disorders in this model. Here, we investigated the effect of
infection followed by drug-cure of these species on the induction of immunity against homologous or heterologous
species challenge. Mice were infected with E. histolytica or E. moshkovskii and treated with metronidazole 14 days
later. Re-challenge with E. histolytica or E. moshkovskii was conducted seven or 28 days following confirmation of
the clearance of amoebae, and the degree of protection compared to non-exposed control mice was evaluated. We
show that primary infection with these amoebae induces a species-specific immune response which protects against
challenge with the homologous, but not a heterologous species. These findings pave the way, therefore, for the
identification of novel amoebae antigens that may become the targets of vaccines and provide a useful platform to
investigate host protective immunity to Entamoeba infections.
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Introduction
Amoebiasis, an infectious disease caused by the parasitic
protozoan Entamoeba histolytica is responsible for over 50
million cases in tropical regions and nearly 100,000 deaths
worldwide each year. Infection is initiated through the ingestion
of cysts in contaminated food or water. E. histolytica primarily
infects the intestine, and may cause a wide range of symptoms
from mild diarrhea to serious dysentery. If untreated, the
parasite can cause life-threatening hemorrhagic colitis and/or
extra-intestinal abscesses [1-5].
E. histolytica trophozoites are able to colonize the human
intestine by adhering to colonic mucins and subsequently to
epithelial cells via cell surface lectin [6]. This lectin is important
for colonic colonization by E. histolytica. A colonization-
blocking vaccine targeting this parasite lectin could prevent
trophozoite adherence and thus provide protection against
subsequent invasive disease [7]. Furthermore, recently, it has
also been reported that there is a correlation between the
presence of anti-lectin fecal immunoglobulin A (IgA) antibodies
and protection from parasitic colonization in humans and mice
[7-9]. These reports suggest that amoebiasis can be controlled
by acquired immunity.
Entamoeba moshkovskii is closely related to Entamoeba
dispar and E. histolytica and is microscopically
indistinguishable from them in its cyst and trophozoite forms
[10]. Recently, we reported that E. moshkovskii causes
diarrhea, colitis and weight loss in mice, and that in
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Bangladeshi children, acquisition of E. moshkovskii infection
was associated with diarrhea [11].
Here, using E. histolytica and E. moshkovskii infections in
mice, we evaluate whether the immunity against reinfection
that occurs following a primary infection is species-specific. We
find that, following a primary infection with either E. histolytica
or E. moshkovskii, mice are protected from re-challenge with a
homologous species, but remained susceptible to a
heterologous species. These results show, for the first time,
that the immunity acquired during primary infection with
Entamoeba spp. confers species-specific protective immunity.
Materials and Methods
Mice
Male CBA/J mice were purchased from Jackson
Laboratories. Animals were maintained under specific
pathogen free conditions at the Animal Research Center for
Tropical Infectious Diseases, Nagasaki University, and were
challenged when they were 5-8 weeks old. All experiments that
involved mice were reviewed and approved by the Committee
for Ethics on Animal Experiments of the Graduate School of
Nagasaki University, and were conducted under the control of
the Guidelines for Animal Experiments in the Graduate School
of Medicine, Nagasaki University, and the Law (No. 105) and
Notification (No. 6) of the Japanese Government pertaining to
the use of experimental animals.
Parasite Culture and Infection
Trophozoites of E. histolytica, originally laboratory strain
HM1:IMSS (American Type Culture Collection, Manassas, VA),
were from Prof. Eric Houpt, University of Virginia, and were
serially passaged in vivo through the ceca of mice [12].
Trophozoites of the E. moshkovskii Laredo strain, were a gift
from Dr. Seiki Kobayashi, Keio University, School of Medicine
(originally from the late professor Louis S. Diamond, NIH,
Bethesda, Maryland). Cecal contents were cultured at 37°C
and 25°C, respectively, in BIS-33 medium supplemented with
heat-inactivated 10% adult bovine serum, 25U/ml penicillin and
25 mg/ml streptomycin [13]. Trophozoites in the logarithmic
growth phase were used in the experiments.
Intracecal inoculation of Entamoeba spp
Trophozoites of E. histolytica HM1:IMSS and E. moshkovskii
Laredo strain were collected after incubating the tubes on ice
for 5-10 minutes. Then, the number of trophozoites was
counted. We anesthetized mice with Domitor (medetomidine
hydrochloride: 0.1mg/kg) and Dormicum (midazolam: 0.1 mg/
kg), shaved their abdomens to incise the skin, exteriorized
each cecum from the peritoneum, and injected 150μl of 1×106
trophozoites into the apical sites of cecum. Then, the cecum
was blotted and the peritoneum and the skin were sutured.
Mice were kept on warming blankets at 37°C throughout
surgery. Survival rates were ≥90% in all mice.
Detection of each Entamoeba spp. by PCR using DNA
extracted from stool of mice
For isolation of Entamoeba DNA from mouse stools, QIAamp
DNA Stool Kits (QIAGEN, Valencia CA) were used according
to manufacturer’s instructions. The primer sequences used for
PCR are as previously described [14].
Administration of metronidazole
For in vivo studies, stock solutions of metronidazole (Sigma
Aldrich, St. Louis, MO) were prepared in 100% dimethyl
sulfoxide at a concentration of 10 mg/mL and stored at 4°C.
The stock solution was diluted 32 times with distilled water to
0.3125 mg/mL, in which the concentration of DMSO was
3.125%. Mice were treated orally with metronidazole at a dose
of 12.5mg/kg of body weight. To cure primary infections with E.
histolytica or with E. moshkovskii, all of mice challenged with E.
histolytica or with E. moshkovskii were treated with 1 mL of
metronidazole orally (0.3125 mg/mL) using gastric intubation
on day 14 post-infection. Naïve mice were also administered
with metronidazole and used as control.
Statistical analysis
Differences between groups were analyzed for statistical
significance with unpaired Student’s t-test and χ2 test. All of
these were performed using Excel software. Probabilities below
0.05 were considered statistically significant.
Results
E. moshkovskii infections were resolved earlier than E.
histolytica infections
We have previously demonstrated that C3H/HeN, C3H/HeJ
and CBA/J mice allow the establishment of E. histolytica and E.
moshkovskii infections, while many strains of mice including
C57BL/6 and BALB/c mice do not, indicating that susceptibility
to E. histolytica and E. moshkovskii infection is dependent on
the genetic background of the host [11,12,15-17]. Trophozoites
of E. histolytica and E. moshkovskii were intracecally
inoculated into CBA/J mice. As expected, both E. histolytica
and E. moshkovskii succeeded in infecting CBA/J mice after
challenge (Figure 1). E. histolytica infected the ceca in
approximately 80% of CBA/J mice (16 of 20) as confirmed by
both culture and PCR of intracecal contents two days after
challenge. In contrast, E. moshkovskii infected the ceca of
CBA/J mice in approximately 65% of mice (13 of 20) at the
same point. At day 14 post-challenge, the infection rate of E.
histolytica was approximately 60% (12 of 20 mice positive),
though that of E. moshkovskii was approximately 5% of mice (1
of 20). At 21 days post-challenge, the infection rate of E.
histolytica was approximately 58% (11 of 19) and that of E.
moshkovskii was 0%.
Metronidazole Sensitivity in E. moshkovskii
So as to treat mice infected with E. histolytica and E.
moshkovskii, the effect of metronidazole on the growth and
survival of E. histolytica and E. moshkovskii trophozoites was
evaluated in vitro. The number of viable cells in glass tubes
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was counted after incubation of E. histolytica and E.
moshkovskii with various concentrations of metronidazole for
48h. The numbers of E. histolytica and E. moshkovskii treated
with metronidazole decreased significantly in a dose dependent
manner (Figure 2).
Amoebic infection induced species-specific protective
immunity
In order to examine whether protection against re-infection
can be induced by primary infection, the mice that allowed the
establishment of the primary infection with E. histolytica or E.
Figure 1.  Entamoeba moshkovskii infections were resolved earlier than Entamoeba histolytica infections.  CBA/J mice
were intracaecally infected with 1 × 106 trophozoites of E. histolytica and E. moshkovskii. Infection rate was monitored by detecting
amoebae in caecal content and by amplifying the amoeba gene from faecal DNA on days 2, 7, 14, and 21. Infection rate of mice
with E. histolytica and E. moshkovskii was shown as open and closed columns, respectively. Values show the representative result
out of 3 individual experiments. Asterisks indicate statistical significance with p < 0.05 between mice infected with E. histolytica and
E. moshkovskii by χ2 test.
doi: 10.1371/journal.pone.0082025.g001
Figure 2.  The effect of metronidazole on the growth and survival of Entamoeba histolytica and Entamoeba moshkovskii
trophozoites was evaluated in vitro.  E. histolytica and E. moshkovskii were incubated with various concentrations of
metronidazole for 48h. Then, the number of viable cells was counted and the proportion of it versus initial number was shown as
open and closed columns, respectively.
doi: 10.1371/journal.pone.0082025.g002
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moshkovskii were treated with metronidazole on day 14 and
used for the secondary challenge. The clearance of amoeba
was confirmed seven days after treatment by PCR. Mice were
kept without any intervention for an additional week, and then
re-challenged with E. histolytica or E. moshkovskii a total of 14
days after treatment (Figure 3A, C). The mice infected with E.
histolytica and treated with metronidazole showed resistance to
homologous re-challenge infection (Figure 3B), but allowed
establishment of infection with the heterologous species E.
moshkovskii in a manner similar to that seen in naive mice
(Figure 3D). Similarly, mice infected with E. moshkovskii and
treated with metronidazole showed resistance to homologous
re-challenge infection with E. moshkovskii (Figure 3D), but
allowed the establishment of infection with the heterologous
species E. histolytica (Figure 3B). Thus, mice that experienced
primary amoebic infection acquired resistance to secondary
homologous species infection. However, primary amoebic
infection did not confer protection against heterologous species
secondary infection. These results show that intestinal amoebic
infection induces species-specific protective immunity.
The protection induced by primary infection lasts more
than four weeks
To examine how long the protection observed against
secondary infection lasts, mice were re-challenged with
homologous or heterologous amoebae on day 35 after
treatment with metronidazole 14 days after primary infection.
The clearance of amoeba was confirmed seven days after
treatment by PCR (Figure 4A, C). As shown in Figure 4B and
4D, 35 days after the treatment of the primary infection, mice
were resistant to homologous re-challenge, but were
susceptible to heterologous species infection. Mice kept for 35
days after the treatment of the primary infection showed
increased infection rates compared to those kept just for 14
days, a phenomenon that was most apparent on day 2 post re-
challenge in the case of E. histolytica and on days 2 and 5 post
challenge with E. moshkovskii (Figure 4B and 4D). These
results suggest that the protection induced by primary infection
may include not only memory responses but also remaining
primary immune responses, both of which are species specific.
Infection-induced species-specific immunity protects
mice from weight loss
During the primary infection, mice infected with E.
moshkovskii suffered severe symptoms. Following re-challenge
with E. moshkovskii (homologous species) 14 days after
treatment of the primary infection, mice did not show any
weight loss (Figure 5A). Slight weight loss was observed,
however, in mice re-challenged 35 days after treatment, but the
severity of weight loss was much smaller than that observed
during the primary infection (Figure 5B). The weight loss was
also ameliorated in mice re-infected with E. histolytica, when
having been given a primary infection with the homologous
species (data not shown).
Discussion
Our results clearly demonstrate that exposure to, and
subsequent drug clearance of, the parasitic amoebae E.
histolytica and E. moshkovskii invokes a strong immune
response that protects mice from subsequent infection with a
homologous species. This protection is species specific,
affording little to no protection against a heterologous species
challenge. The fact that this strong species-specific immunity
was shown to last at least 35 days following the treatment of
the initial infection suggests that memory responses are
involved.
Figure 3.  Amoebic infection induced species-specific protective immunity.  Mice were infected with 1 × 106 trophozoites of
Entamoeba histolytica (open triangle) or Entamoeba moshkovskii (open circle) and treated with metronidazole (Mz) on day 14
following induction of the primary infection. The clearance of amoeba was confirmed seven days after treatment by PCR. Mice were
kept without any intervention for an additional week, and then re-challenged with 1 × 106 trophozoites of E. histolytica (A, B) or E.
moshkovskii (C, D) at 14 days after treatment. The number of mice used was as follows: for naïve→E. histolytica, N=16: for E.
histolytica→E. histolytica, N=20: for E. moshkovskii →E. histolytica, N=20 (A, B); for naïve→E. moshkovskii, N=20: for E.
histolytica→E. moshkovskii, N=20: for E. moshkovskii →E. moshkovskii, N=20 (C, D). Asterisks indicate statistical significance with
p < 0.05 by χ2 test between mice infected with E. histolytica and E. moshkovskii in the primary infection.
doi: 10.1371/journal.pone.0082025.g003
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Despite the fact that it has long been suspected that people
may acquire immunity against amoebae, as older children in
endemic areas are infected less frequently than younger
children [18], this work constitutes the first experimental proof
of this phenomenon. The molecular and cellular mechanisms
responsible for the observed protection have not been
addressed in this work. Mucosal IgA has been reported to be
associated with protection against intestinal amoebiasis in
humans, mice and baboons [7,8,19]. Indeed, monoclonal IgA
specific for the E. histolytica galactose inhibitable adherence
(GalNAc) lectin heavy subunit (HgL) is thought to inhibit its
interaction with a host sugar moiety in colonic mucins, resulting
in the failure of amoebae to settle within the intestines [20].
Furthermore, we and Guo et al. recently reported that IFN-γ
derived from amoeba-specific T cells plays a protective role
against E. moshkovskii (unpublished data) and E. histolytica
[21], respectively, suggesting that T cells as well as antibodies
specific for amoebic antigens are involved in acquired
resistance to intestinal amoebic infections.
The phenomenon of species-specific immunity against
parasitic pathogens has been studied in a number of parasitic
species, perhaps most comprehensively with the Plasmodium
species responsible for malaria [22]. For this pathogen, which
exhibits both species and strain specific immunity, antigenic
variation of major parasite surface antigens such as the
merozoite surface protein 1 (MSP1), induces antibody-
mediated immune responses that are effective only against the
inducing-strain [22,23]. Such highly polymorphic strain- and
species-specific antigens are thought to evolve through the
actions of positive diversifying selection, so that proteins that
are targeted by the host immune response rapidly accumulate
polymorphisms. Here we show, for the first time, that the
phenomenon of species-specific immunity also exists for
Entamoeba spp. It seems probable that this is due to
Figure 4.  The protection induced by primary infection lasts more than four weeks.  Mice were infected with 1 × 106
trophozoites of Entamoeba histolytica (open triangle) or Entamoeba moshkovskii (open circle) and treated with metronidazole (Mz)
on day 14 following induction of the primary infection. The clearance of amoeba was confirmed seven days after treatment by PCR.
Mice were kept without any intervention for 28 days, and re-challenged with 1 × 106 trophozoites of E. histolytica (A, B) or E.
moshkovskii (C, D) at 35 days after treatment. The number of mice used was as follows: for naïve→E. histolytica, N=16: for E.
histolytica→E. histolytica, N=20: for E. moshkovskii →E. histolytica, N=26 (A, B); for naïve→E. moshkovskii, N=15: for E.
histolytica→E. moshkovskii, N=20: for E. moshkovskii →E. moshkovskii, N=20 (C, D). Asterisks indicate statistical significance with
p < 0.05 by χ2 test between mice infected with E. histolytica and E. moshkovskii in the primary infection.
doi: 10.1371/journal.pone.0082025.g004
Figure 5.  The change of body weight was monitored after re-challenging mice with Entamoeba moshkovskii.  The naïve
mice or mice exposed to primary E. moshkovskii infection were re-challenged with 1 × 106 trophozoites of E. moshkovskii at 7 or 28
days after confirming the clearance of primary infection. The studies were repeated 3 times with similar results. Asterisks indicate
statistical significance with p < 0.05 between the groups of mice with primary and secondary infection using unpaired Student’s t-
test.
doi: 10.1371/journal.pone.0082025.g005
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polymorphisms in major antigen target proteins between
species. If so, then such antigens may be identified by
comparative genomics. Of particular interest are the GalNAc-
lectin HgL proteins previously implicated in antibody-mediated
protection against E. histolytica. Nucleotide sequence
comparisons of the genes encoding this protein in E histolytica
and E. moshkovskii may shed further light on this.
We found that E. moshkovskii is susceptible to the anti-
amoeba drug metronidazole both in vitro and in vivo to the
same degree as E. histolytica. This finding supports the use of
this drug in the treatment of pathogenic E. moshkovskii, and
may ease concern of treatment failure following cases of
misdiagnosis of E. moshkovskii as E. histolytica.
In summary, we show that exposure to a single drug cured
amoebic infection confers resistance to re-challenge with the
homologous, but not a heterologous species, for the first time,
in which species-specific acquired immunity has been
demonstrated for amoebic infections. This work paves the way,
therefore, for the identification of novel amoebae antigens that
may become the targets of vaccines.
Acknowledgements
We thank Fumie Hara, Masako Hayashida and Megumi
Hamasaki for animal husbandry; Tomoko Takaya, Hiromi Oda
and Rumiko Kosugi for administrative support; Richard
Culleton for scientific editing; members of Institute of Tropical
Medicine, Nagasaki University and Department of Parasitology,
Graduate School of Medicine, Gunma University for technical
assistance and precious comments.
Author Contributions
Conceived and designed the experiments: CS SH. Performed
the experiments: CS TI KS MH TT SK. Analyzed the data: CS
RC HH SH. Contributed reagents/materials/analysis tools: CS
SK SH. Wrote the manuscript: CS RC SH.
References
1. Bryce J, Boschi-Pinto C, Shibuya K, Black RE (2005) WHO estimates
of the causes of death in children. Lancet 365: 1147-1152. doi:10.1016/
S0140-6736(05)71877-8. PubMed: 15794969.
2. Petri WA Jr., Miller M, Binder HJ, Levine MM, Dillingham R et al. (2008)
Enteric infections, diarrhea, and their impact on function and
development. J Clin Invest 118: 1277-1290. doi:10.1172/JCI34005.
PubMed: 18382740.
3. Guerrant RL, Oriá RB, Moore SR, Oriá MO, Lima AA (2008)
Malnutrition as an enteric infectious disease with long-term effects on
child development. Nutr Rev 66: 487-505. doi:10.1111/j.
1753-4887.2008.00082.x. PubMed: 18752473.
4. Irusen EM, Jackson TF, Simjee AE (1992) Asymptomatic intestinal
colonization by pathogenic Entamoeba histolytica in amebic liver
abscess: prevalence, response to therapy, and pathogenic potential.
Clin Infect Dis 14: 889-893. doi:10.1093/clinids/14.4.889. PubMed:
1576284.
5. Blessmann J, Ali IK, Nu PA, Dinh BT, Viet TQ et al. (2003) Longitudinal
study of intestinal Entamoeba histolytica infections in asymptomatic
adult carriers. J Clin Microbiol 41: 4745-4750. doi:10.1128/JCM.
41.10.4745-4750.2003. PubMed: 14532214.
6. Chadee K, Petri WA Jr., Innes DJ, Ravdin JI (1987) Rat and human
colonic mucins bind to and inhibit adherence lectin of Entamoeba
histolytica. J Clin Invest 80: 1245-1254. doi:10.1172/JCI113199.
PubMed: 2890655.
7. Houpt E, Barroso L, Lockhart L, Wright R, Cramer C et al. (2004)
Prevention of intestinal amebiasis by vaccination with the Entamoeba
histolytica Gal/GalNac lectin. Vaccine 22: 611-617. doi:10.1016/
j.vaccine.2003.09.003. PubMed: 14741152.
8. Haque R, Ali IM, Sack RB, Farr BM, Ramakrishnan G et al. (2001)
Amebiasis and mucosal IgA antibody against the Entamoeba histolytica
adherence lectin in Bangladeshi children. J Infect Dis 183: 1787-1793.
doi:10.1086/320740. PubMed: 11372032.
9. Haque R, Duggal P, Ali IM, Hossain MB, Mondal D et al. (2002) Innate
and acquired resistance to amebiasis in bangladeshi children. J Infect
Dis 186: 547-552. doi:10.1086/341566. PubMed: 12195383.
10. Fotedar R, Stark D, Marriott D, Ellis J, Harkness J (2008) Entamoeba
moshkovskii infections in Sydney, Australia. Eur J Clin Microbiol Infect
Dis 27: 133-137. doi:10.1007/s10096-007-0399-9. PubMed: 17957394.
11. Shimokawa C, Kabir M, Taniuchi M, Mondal D, Kobayashi S et al.
(2012) Entamoeba moshkovskii is associated with diarrhea in infants
and causes diarrhea and colitis in mice. J Infect Dis 206: 744-751. doi:
10.1093/infdis/jis414. PubMed: 22723640.
12. Hamano S, Asgharpour A, Stroup SE, Wynn TA, Leiter EH et al. (2006)
Resistance of C57BL/6 mice to amoebiasis is mediated by
nonhemopoietic cells but requires hemopoietic IL-10 production. J
Immunol 177: 1208-1213. PubMed: 16818779.
13. Diamond LS, Harlow DR, Cunnick CC (1978) A new medium for the
axenic cultivation of Entamoeba histolytica and other Entamoeba.
Trans R Soc Trop Med Hyg 72: 431-432. doi:
10.1016/0035-9203(78)90144-X. PubMed: 212851.
14. Hamzah Z, Petmitr S, Mungthin M, Leelayoova S, Chavalitshewinkoon-
Petmitr P (2006) Differential detection of Entamoeba histolytica,
Entamoeba dispar, and Entamoeba moshkovskii by a single-round
PCR assay. J Clin Microbiol 44: 3196-3200. doi:10.1128/JCM.
00778-06. PubMed: 16954247.
15. Houpt ER, Glembocki DJ, Obrig TG, Moskaluk CA, Lockhart LA et al.
(2002) The mouse model of amebic colitis reveals mouse strain
susceptibility to infection and exacerbation of disease by CD4+ T cells.
J Immunol 169: 4496-4503. PubMed: 12370386.
16. Asgharpour A, Gilchrist C, Baba D, Hamano S, Houpt E (2005)
Resistance to intestinal Entamoeba histolytica infection is conferred by
innate immunity and Gr-1+ cells. Infect Immun 73: 4522-4529. doi:
10.1128/IAI.73.8.4522-4529.2005. PubMed: 16040963.
17. Hamano S, Becker S, Asgharpour A, Ocasio YP, Stroup SE et al.
(2008) Gender and genetic control of resistance to intestinal amebiasis
in inbred mice. Genes Immun 9: 452-461. doi:10.1038/gene.2008.37.
PubMed: 18480826.
18. Haque R, Mondal D, Duggal P, Kabir M, Roy S et al. (2006)
Entamoeba histolytica infection in children and protection from
subsequent amebiasis. Infect Immun 74: 904-909. doi:10.1128/IAI.
74.2.904-909.2006. PubMed: 16428733.
19. Abd Alla MD, Wolf R, White GL, Kosanke SD, Cary D et al. (2012)
Efficacy of a Gal-lectin subunit vaccine against experimental
Entamoeba histolytica infection and colitis in baboons (Papio sp.).
Vaccine 30: 3068-3075. doi:10.1016/j.vaccine.2012.02.066. PubMed:
22406457.
20. Chadee K, Johnson ML, Orozco E, Petri WA Jr., Ravdin JI (1988)
Binding and internalization of rat colonic mucins by the galactose/N-
acetyl-D-galactosamine adherence lectin of Entamoeba histolytica. J
Infect Dis 158: 398-406. doi:10.1093/infdis/158.2.398. PubMed:
2900266.
21. Guo X, Stroup SE, Houpt ER (2008) Persistence of Entamoeba
histolytica infection in CBA mice owes to intestinal IL-4 production and
inhibition of protective IFN-γ. Mucosal Immunol 1: 139-146. doi:
10.1038/mi.2007.18. PubMed: 19079171.
22. Inoue M, Tang J, Miyakoda M, Kaneko O, Yui K et al. (2012) The
species specificity of immunity generated by live whole organism
immunisation with erythrocytic and pre-erythrocytic stages of rodent
malaria parasites and implications for vaccine development. Int J
Parasitol 42: 859-870. doi:10.1016/j.ijpara.2012.07.001. PubMed:
22846785.
23. Martinelli A, Cheesman S, Hunt P, Culleton R, Raza A et al. (2005) A
genetic approach to the de novo identification of targets of strain-
specific immunity in malaria parasites. Proc Natl Acad Sci U S A 102:
814-819. doi:10.1073/pnas.0405097102. PubMed: 15640359.
Species-Specific Immunity Induced by Entamoeba
PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e82025
